



November 6, 2025

To whom it may concern:

Company name: SanBio Co., Ltd.
Representative: Keita Mori, Representative Director
and President
(Code Number: 4592 Tokyo Stock
Exchange-Growth)
Contact: Yoshihiro Kakutani, Corporate Officer,
Management Administration
(TEL. +81-3-6264-3481)

**Announcement of Determination of Issue Price and Other Matters
for Issuance of New Shares Through an International Offering**

SanBio Co., Ltd. (the "Company") hereby announces that the Company has determined the issue price and other matters in relation to the issuance of new shares through an international offering (the "International Offering"), as resolved at the meeting of the Board of Directors dated November 6, 2025, as follows.

1. Issuance of New Shares through the International Offering

(1)	Issue Price (Offer Price) (Note)	<u>2,487 yen per share</u>
(2)	Total Amount of Issue Price (Offer Price) (Note)	<u>14,922,000,000 yen</u>
(3)	Amount to be Paid in	<u>2,377.64 yen per share</u>
(4)	Total Amount to be Paid in	<u>14,265,840,000 yen</u>
(5)	Amount of Capital Stock and Capital Surplus to be Increased	<u>Amount of Increase in Capital Stock</u> <u>7,132,920,000 yen</u> <u>Amount of Increase in Capital Surplus</u> <u>7,132,920,000 yen</u>
(6)	Payment Date	<u>November 21, 2025 (Fri)</u>
(7)	Delivery Date	<u>November 25, 2025 (Tue)</u>

Note: The underwriter will purchase and underwrite the shares at the amount to be paid in and offer the shares at the issue price (the offer price)

Reference

1. Calculation of Issue Price (Offer Price)

(1) Calculation Reference Date and Price	November 6, 2025 (Thu)	2,734 yen
(2) Discount Rate		9.03%

2. Intended Use of Funds Raised

The estimated net proceeds of 14,202 million yen from the International Offering are expected to be applied to:

- 1) 1,393 million yen by the end of December 2027 for the establishment of AKUUGO® adoption infrastructure in Japan, primarily for preparation and implementation of post-marketing clinical trials and their data analysis, as well as for the establishment of mechanisms infrastructure to ensure the safe and appropriate use of AKUUGO®.
- 2) 9,442 million yen by the end of December 2027 for the costs pertaining to clinical trials for the SB623 traumatic brain injury program in the U.S. market, primarily covering the development of clinical trial protocols, the conduct of clinical trials and the analysis of these data.
- 3) 3,367 million yen by the end of December 2027 for the costs pertaining to clinical trials for the SB623 cerebral infarction program in Japan, primarily covering the development of clinical trial protocols, the conduct of clinical trials and the analysis of these data.

Note: This press release does not constitute an offer of any securities for sale. This press release has been prepared for the sole purpose of publicly announcing the International Offering, and not for the purpose of soliciting investment or engaging in any other similar activities within or outside Japan. This press release is not an offer of securities for sale in the United States. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities referred to herein have not been, and will not be registered under the Securities Act. If any public offering of securities is made in the United States, it will be by means of a prospectus that may be obtained from the Company that will contain detailed information about the Company and its management, as well as financial statements of the Company. The securities referred to herein will not be publicly offered in the United States and a prospectus in English has not been prepared for the International Offering. As the offering in connection with the issuance of new shares referred to herein will be made outside Japan and only to the non-residents of Japan, registrations or notifications under the Financial Instruments and Exchange Act of Japan (the "FIEA") will not be made, and a prospectus under the FIEA will not be prepared.

[End of Document]

Note on translation

This is a translation of the original Japanese document and is provided for informational purpose only. If there are any discrepancies between this and the original, the original Japanese document prevails.